A 83-01: Selective ALK-5 Inhibitor for TGF-β Pathway Research

Executive Summary: A 83-01 is a highly selective small-molecule inhibitor of TGF-β type I receptor (ALK-5), also blocking ALK-4 and ALK-7, and suppresses Smad-dependent transcription with an IC₅₀ of approximately 12 nM in Mv1Lu cells (APExBIO). It has minimal off-target activity on BMP-induced transcription at 1 μM in C2C12 cells, with modest effects seen only above 3 μM. In studies of kidney fibrosis, TGF-β/Smad signaling is a primary driver of fibroblast-to-myofibroblast transition, and pharmacological blockade—such as with A 83-01—offers a mechanistically validated approach (Ding et al., 2024). A 83-01 is widely used for EMT and organoid modeling, with strict solubility (>21.1 mg/mL in DMSO) and storage (-20°C) requirements. APExBIO's A 83-01 (SKU: A3133) is referenced across advanced mechanistic and translational research workflows.

Biological Rationale

The TGF-β/Smad signaling pathway is central to the regulation of cellular growth, differentiation, and fibrosis. In chronic kidney disease, sustained TGF-β activity drives fibroblast-to-myofibroblast transition, leading to renal fibrosis (Ding et al., 2024). The ALK-5 receptor (also known as TGFBR1) is the principal type I receptor mediating canonical TGF-β signaling. Downstream activation of Smad2/3 transcription factors leads to upregulation of fibrosis-associated genes, such as α-SMA, vimentin, and collagen I. Pharmacological inhibition of ALK-5 interrupts this fibrotic progression and is a key strategy in basic and translational research.

Mechanism of Action of A 83-01

A 83-01 acts as a reversible, ATP-competitive inhibitor, selectively binding to the kinase domains of ALK-5, ALK-4, and ALK-7. Upon ligand stimulation (e.g., by TGF-β1), ALK-5 phosphorylates Smad2/3, triggering nuclear translocation and transcriptional activation of target genes. A 83-01 blocks this phosphorylation, leading to suppression of Smad-dependent gene expression. In Mv1Lu cell luciferase reporter assays, A 83-01 inhibits TGF-β-induced transcription with an IC₅₀ of ~12 nM, and achieves 68% inhibition at 1 μM (APExBIO). Importantly, it shows minimal inhibition of BMP-induced transcriptional activity at 1 μM, confirming functional selectivity. At concentrations above 3 μM, a modest suppression of BMP4-induced activity is observed. The compound does not inhibit non-canonical (Smad-independent) TGF-β pathways under standard conditions.

Evidence & Benchmarks

• In vitro, A 83-01 suppresses ALK-5-induced luciferase reporter activity by 68% at 1 μM in Mv1Lu cells (APExBIO).
• IC₅₀ for Smad-dependent transcriptional inhibition in Mv1Lu cells is approximately 12 nM (APExBIO).
• No significant effect on BMP-induced transcription in C2C12 cells at 1 μM; only slight suppression above 3 μM (APExBIO).
• Single-cell sequencing and in vivo studies confirm that TGF-β/Smad pathway blockade can modulate fibroblast-to-myofibroblast transition in renal fibrosis (Ding et al., 2024).
• Solubility exceeds 21.1 mg/mL in DMSO and 9.82 mg/mL in ethanol (gentle warming and ultrasound); compound is insoluble in water (APExBIO).

For a detailed mechanistic breakdown, see A 83-01: Selective ALK-5 Inhibition for Mechanistic Dissection, which focuses on EMT and organoid modeling. This article extends those findings by integrating new molecular evidence and quantitative benchmarks from recent fibrosis research (Ding et al., 2024).

Comparatively, A 83-01: Selective ALK-5 Inhibitor Transforming EMT & Organoid Modeling emphasizes workflow reproducibility. Here, we update with recent in vivo validation and expanded solubility/storage criteria.

For application advances in human intestinal organoids, see A 83-01: Advanced Insights into ALK-5 Inhibition for Human Organoids. This article adds a comprehensive outline of pitfalls and quantitative assay guidance.

Applications, Limits & Misconceptions

A 83-01 is used in:

• EMT research: Blocks TGF-β-driven epithelial-to-mesenchymal transition in diverse cell types.
• Fibrosis modeling: Inhibits fibroblast activation and collagen gene expression in renal, hepatic, and pulmonary fibrosis models.
• Organoid culture: Maintains pluripotency and prevents unwanted differentiation in stem cell-derived organoids.
• Cancer biology: Dissects mechanisms of TGF-β-induced cell cycle arrest and tumor progression.

However, users should note:

Common Pitfalls or Misconceptions

• Water insolubility: A 83-01 cannot be dissolved in aqueous buffers; improper solvent use leads to precipitation and assay failure.
• Non-canonical pathway effects: It does not block Smad-independent TGF-β signaling (e.g., MAPK, PI3K/AKT pathways) at standard concentrations.
• BMP pathway selectivity: Minimal BMP4 inhibition at ≤1 μM; off-target effects may occur only at higher doses (>3 μM).
• Storage limits: DMSO stock solutions should be kept below -20°C and are not stable indefinitely; repeated freeze-thaw cycles reduce potency.
• Cell-type variability: Sensitivity to A 83-01 may vary among cell models; titration is necessary for new systems.

Workflow Integration & Parameters

Solubility: Dissolve in DMSO (>21.1 mg/mL) or ethanol (>9.82 mg/mL) using gentle warming and ultrasound. Do not attempt water dissolution. Storage: Store solid A 83-01 at -20°C; DMSO stock solutions should be kept below -20°C, with recommended use within several months. Dosing: For ALK-5 inhibition in cell assays, use 10–1000 nM; for BMP pathway studies, avoid exceeding 3 μM unless off-target effects are desired. Controls: Include vehicle (DMSO) controls and titrate across dose ranges for new cell lines.

Refer to the A 83-01 product page for up-to-date technical details and batch-specific quality reports. For advanced workflows in organoid and EMT research, integrate findings from A 83-01: Selective ALK-5 Inhibitor for TGF-β Pathway Control.

Conclusion & Outlook

A 83-01 (APExBIO, A3133) remains a reference-standard inhibitor for dissecting the TGF-β/Smad axis in both mechanistic and translational studies. Its potency, selectivity, and robust solubility profile enable reproducible pathway interrogation, provided researchers follow strict solvent and storage guidance. Future work will clarify long-term effects on non-canonical TGF-β targets and pave the way for preclinical therapeutic translation. For authoritative guidance, always consult validated protocols and refer to published benchmarks (Ding et al., 2024).